CytRx Corporation (CYTR) belongs to the “Healthcare” sector with an industry focus on “Biotechnology”, with Mr. Steven A. Kriegsman as Chairman of The Board, Chief Exec. Officer and Pres. The company has been one of the biggest innovators in “Biotechnology” employing approximately 27 full time employees. Key Statistics: The stock subtracted in the prior trading … - From Free Observer
If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, CYTR earned gross profit of 0, in 2015 0 gross profit, while in 2016 CytRx Corporation (CYTR) produced 0 profit.
Currently the shares of CytRx Corporation (CYTR) has a trading volume of 8.71 Million shares, with an average trading volume of 16850 shares – with shares dropping to a 52 week low of $0.36, and the company’s shares hitting a 52 week high of $ 3.54.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for CytRx Corporation the EPS stands at -0.06 for the previous quarter, while the analysts predicted the EPS of the stock to be -0.11, suggesting the stock exceeded the analysts’ expectations.
Stock is currently moving with a positive distance from the 200 day simple moving average of approximately 56.65%, and has a solid year to date (YTD) performance of 117.76% which means the stock is constantly adding to its value from the previous fiscal year end price.